Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
‍
Are you a health professional practicing in the United States?
Yes, take me to Medical Affairs
No, Take me to ParatekPharma.com

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Medical Information Request
Publications & Presentations
Grants & Funding
Product Resources
Disease Education Resources
Medical Affairs
Publications & Presentations

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscript Icon
Manuscripts
Poster Icon
Posters

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Clear all
Apply
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Real World Evidence
Dabie bandavirus and Mycoplasma pneumoniae co-infection: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Tu
Citation #
(1):47
Date
January 2025
Real World Evidence
Compassionate Use of Omadacycline in a Down Syndrome Pre-Schooler With Critically Ill Atypical Pneumonia Caused by Macrolide-Resistant Mycoplasma Pneumoniae
Resource Type
Manuscript
Areas of Interest
Other
Author Name
Wu
Citation #
18:391-400
Date
January 2025
Real World Evidence
Treatment of Mycobacterium abscessus-Related Peritoneal Dialysis-Associated Peritonitis with Clofazimine and Omadacycline
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Colindres
Citation #
4(4): 8
Date
December 2024
Clinical
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Sanders
Citation #
63(12):1701-1709
Date
December 2024
Clinical
Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Rodriguez
Citation #
12:2637-2648
Date
December 2024
Real World Evidence
Omadacycline for the treatment of severe Legionella pneumophila pneumonia complicated with multiple organ dysfunction: a case report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Lv
Citation #
110(4):116553
Date
December 2024
Real World Evidence
Omadacycline for Diverse Infections in China: A Real-World Analysis of Efficacy and Safety
Resource Type
Manuscript
Areas of Interest
Other
Author Name
Gao
Citation #
13(12):2509-2526
Date
December 2024
Pharmacokinetics - Pharmacodynamics
Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Xu
Citation #
36(8):706-716
Date
December 2024
Real World Evidence
Omadacycline in the Treatment of Chlamydia psittaci Pneumonia: A Retrospective Study on Efficacy and Safety
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Li
Citation #
85(11):1–12
Date
November 2024
Real World Evidence
Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Cristinziano
Citation #
15(1):10360
Date
November 2024
Pharmacokinetics - Pharmacodynamics
Clinically important interactions of macrolides and tetracyclines with dietary interventions—a systematic review with meta-analyses
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Wiesner
Citation #
79(11):2762-2791.
Date
November 2024
Real World Evidence
V–V ECMO for severe Chlamydia psittaci pneumonia presenting with sudden cardiac arrest: A case report and literature review
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Chen
Citation #
103(45):e39808
Date
November 2024
Non-Clinical
Immunomodulatory activity of omadacycline in vitro and in a murine model of acute lung injury
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Sanders
Citation #
9 (11):e0067124
Date
November 2024
Microbiology
Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Mudde
Citation #
28(11):554-556
Date
November 2024
Pharmacokinetics - Pharmacodynamics
Evaluating omadacycline dosing regimens against drug-resistant pathogens including Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Wei
Citation #
36(7):532-539
Date
November 2024
Real World Evidence
Chronic dacryocystitis due to Mycobacterium abscessus
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Solbes-Gochicoa
Citation #
Online ahead of print
Date
October 2024
Review
Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Draper
Citation #
81 (21):e677-e683
Date
October 2024
Real World Evidence
Possible omadacycline induce acute pancreatitis: a case report and literature review
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Xu
Citation #
24(1):1072
Date
September 2024
Real World Evidence
Current challenges in pulmonary nontuberculous mycobacterial infection: a case series with literature review
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Metersky
Citation #
136(7):770-781
Date
September 2024
Non-Clinical
Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis
Resource Type
Manuscript
Areas of Interest
Biothreats
Author Name
Heine
Citation #
68(9):e0059524
Date
September 2024
Pharmacokinetics - Pharmacodynamics
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Bhavnani
Citation #
online ahead of print
Date
September 2024
Microbiology
High Rates of Non-susceptibility to Common Oral Antibiotics in Streptococcus pneumoniae Clinical Isolates from the United States (2019-2021)
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Deshpande
Citation #
ofae470
Date
August 2024
Review
Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database
Resource Type
Manuscript
Areas of Interest
Multiple
Author Name
Xiong
Citation #
Date
August 2024
Real World Evidence
Case report: a co-occurring case of severe Mycoplasma pneumoniae pneumonia and Anti-IgLON5 antibody-associated encephalitis in a pediatric patient
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Ye
Citation #
11:1393540
Date
August 2024
Show More Resources
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2025
CHEST 2025
accordio_arrow
CHEST 2025
IDWeek 2025
accordio_arrow
IDWeek 2025
MAD-ID 2025
accordio_arrow
MAD-ID 2025
ATS 2025
accordio_arrow
ATS 2025
SAWC 2025
accordio_arrow
SAWC 2025
ESCMID Global
accordio_arrow
ESCMID Global 2025
2024
IDWeek 2024
accordio_arrow
IDWeek 2024
MHSRS
accordio_arrow
MHSRS 2024
ASM Microbe
accordio_arrow
ASM Microbe 2024
ESCMID Global (formally ECCMID)
accordio_arrow
ESCMID Global (formally ECCMID)
Texas Medical Center AMR & Stewardship
accordio_arrow
Texas Medical Center AMR & Stewardship
2023
ASM Microbe
accordio_arrow
ASM Microbe 2023
IDWeek
accordio_arrow
IDWeek 2023
ECCMID
accordio_arrow
ECCMID 2023
2022
IDWeek
accordio_arrow
IDWeek 2022
MHSRS
accordio_arrow
MHSRS 2022
ASM-Microbe
accordio_arrow
ASM-Microbe 2022
No items found.
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
View All
Microbiological Outcomes of Oral Omadacycline Treatment in Adults with Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc): Results from a Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Trial
Omadacycline outcomes in community-acquired bacterial pneumonia: pooled efficacy and safety from the Phase 3 OPTIC and OPTIC-2 trials.
Omadacycline was Shown to Preserve the Microbiome in a Murine Model of Post-Influenza MRSA Pneumonia
Health-related quality-of-life outcomes in OPTIC-2: A randomized, controlled, Phase 3b trial of omadacycline vs. moxifloxacin in community-acquired bacterial pneumonia
In Vitro Activity of Omadacycline and Comparator Agents Against Periodontal Pathogens
Susceptibility of Omadacycline in Bone and Joint Infections: Pathogen Susceptibility and Regimen Decisions from an Ongoing Randomized Controlled Trial
Pooled Microbiological Outcomes from the Phase 3, Randomized OPTIC and OPTIC-2 Trials of Omadacycline vs Moxifloxacin in Community-Acquired Bacterial Pneumonia
Real-world Efficacy and Safety of Omadacycline in Immunocompromised Patients
Tigecycline as a Surrogate for Omadacycline Susceptibility in Enterococcus faecalis and Enterococcus faecium
Omadacycline for Community-acquired Bacterial Pneumonia (OPTIC-2): A Phase 3b Randomized, Double-blind, Multicenter, Controlled, Noninferiority Trial
A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adults With Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) Caused by Mycobacterium Abscessus
Prescription Patterns among Outpatients with Antibiotic Failure/Intolerance in the Treatment ​ of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): A 2020 to 2022 Retrospective Cohort Study​
Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice
Omadacycline for Skin and Soft Tissue Infections: A Multicenter Retrospective Analysis of Efficacy and Safety in Real-World Clinical Practice
Clinical Efficacy and Safety of Omadacycline in the Treatment of Enterococcal Infections
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)
Omadacycline demonstrated efficacy as both therapeutic treatment and post-exposure prophylaxis against inhalation anthrax and pneumonic plague in cynomolgus macaques
Clinical and microbiological outcomes of omadacycline for pulmonary Mycobacterium abscessus complex
Evaluation of Fecal Pharmacokinetics and Metagenomic Changes Following the Administration of Intravenous Omadacycline to Healthy Subjects
Current Prescribing Practices and Guideline Concordance for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) among Outpatient and Urgent Care Visits
In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020
Safety of Omadacycline Versus Standard-of-Care Oral Antibiotic Treatment for Bone and Joint Infections: Interim Results From an Open-Label, Non-Inferiority, Randomized Controlled Trial
Omadacycline is Active Against Multidrug Resistant Bacillus Anthracis Strains Resistant to Tetracyclines
In Vitro Interaction of Omadacycline in Combination with Melatonin against Carbapenemase producing Klebsiella pneumoniae
Evaluation of Omadacycline Treatment for Osteomyelitis
Omadacycline alone and in combination as a treatment option for Mycobacterium avium infections
Minimum inhibitory concentrations (MICs) of tigecycline correlate strongly with those of omadacycline
Real-World Outpatient Use of Omadacycline for Bone and Joint Infections
Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits
Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis
In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme
Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
No items found.
No items found.
No items found.

Contact Us

If you would like to speak to a Paratek Medical Information Professional please call 1-833-PARATEK (1-833-727-2835) or email medinfo@paratekpharma.com. Otherwise please see below.

Medical Information
If you would like to speak to a Paratek Medical Information Professional or speak with a Field Medical professional about NUZYRA®:
‍
Call: 1-833-PARATEK (1-833-727-2835)
Email: medinfo@paratekpharma.com

With our commitment to patient safety, if you are reporting an adverse event or product complaint, please report as much relevant information as possible which may include product indication, lot number and return availability.

If you would like to speak to a Paratek Medical Information Professional or speak with a Field Medical professional about XHANCE®:

Call:  1-833-678-6673
Email:  ReportAE@optinose.com
Report a Product Complaint
To report a Product Quality Complaint for NUZYRA®:

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com

To report a Product Quality Complaint for XHANCE®:
Call:  1-833-678-6673
Email:  ReportAE@optinose.com
Report an Adverse Event
To report an Adverse Event for NUZYRA®:

Call: 1-833-PARATEK (1-833-727-2835)
Email: drugsafety@propharmagroup.com

To report an Adverse Event for XHANCE®:
 Call:  1-833-678-6673
Email:  ReportAE@optinose.com

You can also contact the FDA:

Call:  1-800-FDA-1088
Email: www.fda.gov/medwatch

Privacy Policy | Terms and Conditions | Social Media Guidelines | Compliance Program | Expanded Access Policy

© 2024 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-COR-0050-01 06/24